MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Sanofi

Отворен

52.81 -1.14

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

52.2

Максимум

53.69

Ключови измерители

By Trading Economics

Приходи

-2.3B

499M

Продажби

-6.5B

7.6B

P/E

Средно за сектора

20.372

57.333

EPS

0.682

Дивидентна доходност

4.34

Марж на печалбата

6.539

Служители

82,878

EBITDA

-3.7B

563M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+20.71% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.34%

2.63%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-11B

126B

Предишно отваряне

53.95

Предишно затваряне

52.81

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Sanofi Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 08:52 ч. UTC

Печалби

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24.04.2025 г., 05:44 ч. UTC

Печалби

Sanofi Sales, Profit Beat Expectations

20.03.2025 г., 06:43 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

3.02.2025 г., 13:19 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

3.02.2025 г., 09:31 ч. UTC

Придобивния, сливания и поглъщания

Correction to L'Oreal article

3.02.2025 г., 07:09 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

24.04.2025 г., 12:54 ч. UTC

Пазарно говорене
Печалби

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24.04.2025 г., 10:06 ч. UTC

Пазарно говорене
Печалби

Sanofi Starts the Year Strong -- Market Talk

3.04.2025 г., 07:51 ч. UTC

Пазарно говорене

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

20.03.2025 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20.03.2025 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20.03.2025 г., 06:04 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Pay $600M Upfront

20.03.2025 г., 06:02 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20.03.2025 г., 06:00 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

19.02.2025 г., 06:35 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19.02.2025 г., 06:34 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19.02.2025 г., 06:34 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19.02.2025 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19.02.2025 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19.02.2025 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19.02.2025 г., 06:32 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19.02.2025 г., 06:31 ч. UTC

Придобивния, сливания и поглъщания

Sanofi, CD&R Sign Opella Share Purchase Agreement

3.02.2025 г., 06:37 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Says Transaction Is Part of Its Share Buyback Program

3.02.2025 г., 06:35 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal: Sale Should Be Finalized in Coming Days

3.02.2025 г., 06:35 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

3.02.2025 г., 06:34 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

3.02.2025 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

3.02.2025 г., 06:32 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

3.02.2025 г., 06:31 ч. UTC

Придобивния, сливания и поглъщания

L'Oreal to Sell Sanofi Stake for EUR3B

Сравнение с други в отрасъла

Ценова промяна

Sanofi Прогноза

Ценова цел

By TipRanks

20.71% нагоре

12-месечна прогноза

Среден 64 USD  20.71%

Висок 65 USD

Нисък 63 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

3

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

50.51 / N/AПодкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.